DK143436B - PROCEDURE FOR PREPARING TABLETS WITH A HIGH CONTENT OF ANTIOB LD OF ANTIBIOTICS - Google Patents
PROCEDURE FOR PREPARING TABLETS WITH A HIGH CONTENT OF ANTIOB LD OF ANTIBIOTICS Download PDFInfo
- Publication number
- DK143436B DK143436B DK565773AA DK565773A DK143436B DK 143436 B DK143436 B DK 143436B DK 565773A A DK565773A A DK 565773AA DK 565773 A DK565773 A DK 565773A DK 143436 B DK143436 B DK 143436B
- Authority
- DK
- Denmark
- Prior art keywords
- tablets
- antibiotics
- starch
- high content
- antiob
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
U3A36 oU3A36 o
Opfindelsen angår en fremgangsmåde til fremstilling af tabletter med et højt indhold af antibiotika af penicilin-og cephalosporintypen.The invention relates to a process for the preparation of tablets having a high content of penicilin and cephalosporin antibiotics.
Ved den orale terapi med antibiotika anvendes der 5 til behandling af infektioner i tiltagende grad højere doseringer for hurtigt at opnå et tilstrækkeligt højt blodspejl af lægemidlet i.patienten.In the oral therapy with antibiotics, 5 are used to treat infections at increasingly higher doses to rapidly obtain a sufficiently high blood level of the drug in the patient.
Ikke sjældent indgives der enkeltdoseringer på indtil flere gram af antibiotiket.Not infrequently, single doses of up to several grams of antibiotic are administered.
10 Det er derfor nødvendigt at udvikle orale lægemiddel- :10 It is therefore necessary to develop oral drug:
former af disse antibiotika, der udviser et indhold af antibiotiket, der er så stort som muligt. Da antibiotika for det meste har en meget ubehagelig bitter smag, kan man kun udvælge lægemiddelformer, der kan siuges hele uden vanskeligheder. De 15 kan eventuelt yderligere have et overtræk. :Mforms of these antibiotics that exhibit a content of the antibiotic that is as large as possible. As antibiotics usually have a very unpleasant bitter taste, only drug forms can be selected that can be sucked whole without difficulty. The 15 may optionally have a further coating. : M
Disse tabletter må efter indtagelsen i fordøjelseskanalen, hurtigt nedbrydes for at frigive det virksomme stof til resorption.These tablets, after ingestion in the digestive tract, must rapidly decompose to release the active substance for resorption.
Ved bestemt formgivning (f.eks. på oval eller oblong-20 form) kan synkeligheden af også tabletter med et højt indhold af virksomt stof lettes.In certain molding (eg in oval or oblong form) the visibility of also tablets with a high content of active substance can be facilitated.
Lægemiddelformer, der uanset størrelsen kan siuges hele, har - svarende til volumenet af tabletblandingen - maksimale vægte på ca. 0,25 til 3 g.Pharmaceutical forms which, irrespective of size, can be fully aspirated, have - corresponding to the volume of the tablet mixture - maximum weights of approx. 0.25 to 3 g.
25 For at sikre optimale egenskaber af tabletterne og., deres fremstilling på moderne, hurtigløbende maskiner sættes der til de virksomme stoffer alt efter deres flyde- og presseforhold sædvanlige kendte hjælpestoffer, som ikke sjældent overgår mængden af virksomt stof flere gange. I normale 30 tilfælde er mængder af hjælpestof på 30% og mere nødvendige for at sikre, at lægemiddelstoffet kan tabletteres, og lægemiddelformen får en god kvalitet.25 In order to ensure optimal properties of the tablets and their manufacture on modern, fast-running machines, the active substances are added to the active substances according to their known flowing and pressing conditions, which do not infrequently exceed the amount of active substance several times. In normal 30 cases, amounts of adjuvant of 30% and more are needed to ensure that the drug can be tableted and the drug form is of good quality.
Som hjælpestoffer skal f.eks. nævnes: Fortyndingsmidler, såsom mælkesukker og sukker, bindemidler, såsom 35 stivelse og cellulosederivater, sprængmidler, såsom stivelsø og ultraamylopectin, og smøremidler, såsom talkum og magnesium-stearat.As auxiliary substances, for example. Mention is made of diluents such as milk sugar and sugar, binders such as starch and cellulose derivatives, disintegrants such as starch and ultra amylopectin, and lubricants such as talc and magnesium stearate.
2 1434362 143436
OISLAND
Ved udviklingen af tablettilberedninger må udvalget af egnede hjælpestoffer ske således, at der dannes strømningsdygtige blandinger eller granulater, ud fra hvilke der kan fremstilles tabletter med optimale egenskaber med hensyn 5 til nedbrydning, frigivelse af virksomt stof, hårdhed, brud-barhed og udseende ved en rationel fremstilling.In the development of tablet preparations, the selection of suitable excipients must be such as to produce flowable mixtures or granules from which tablets with optimum properties with respect to degradation, release of active substance, hardness, fragility and appearance can be produced. rational manufacture.
Ved tabletter med høj dosering af virksomt stof er det særlig vigtigt at holde mængden af hjælpestoffer ringe, således at tabletterne ikke bliver for store. På den anden 10 side må disse tabletter imidlertid også udvise tilfredsstillende egenskaber, især et godt henfald og en god frigivelse af det Virksomme stof.For high doses of active substance it is especially important to keep the amount of excipients low so that the tablets do not become too large. On the other hand, however, these tablets must also exhibit satisfactory properties, especially good decay and good release of the active substance.
En række antibiotika, især penicilliner og cephalc-sporiner samt deres derivater, udviser meget dårlige strømnings- 15 forhold. På grund af elektrostatisk opladning udviser de allerede ved bevægelse i en flaske en tendens til aggregatdannelse og til sammenklumpning, således at fagmanden kun ved tilsætning af høje mængder af hjælpestoffer kan fremstille tilstrækkelig tabletterbare blandinger eller granulater.A variety of antibiotics, particularly penicillins and cephalc-sporins, as well as their derivatives, exhibit very poor flow conditions. Due to electrostatic charge, they already exhibit a tendency for aggregate formation and aggregation when moving in a bottle, so that the skilled artisan can produce sufficient tabletable mixtures or granules only by the addition of high amounts of excipients.
20 På den anden side kræver den rationelle produktion af tabletter på maskiner med høj kapacitet blandinger og granulater af virksomt stof, der også strømmer tilstrækkeligt ved høj hastighed af tabletteringsmaskinen. Også store matricer i oblongform må fyldes ensartet for at sikre en ens-25 artet dosering. Lågdannelse og andre mekaniske beskadigelser af tabletterne, der især optræder ved store pressehastigheder, skal undgås. Disse ulemper overvindes ved, at der tilsættes store mængder af godt strømmende hjælpestoffer.20 On the other hand, the rational production of tablets on high-capacity machines requires active ingredient blends and granules that also flow sufficiently at the high speed of the tableting machine. Also, large matrices in oblong form must be filled uniformly to ensure uniform dosing. Lid formation and other mechanical damage to the tablets, which occur especially at high press speeds, must be avoided. These disadvantages are overcome by adding large quantities of well-flowing auxiliaries.
Det var altså fuldstændigt overraskende for en fagmand, 30 at en upåklagelig rationel produktion af sådanne tabletter, dvs. med højt indhold af virksomt stof og ringe mængder hjælpestoffer, ville være muligt.Thus, it was completely surprising to one skilled in the art that an impeccably rational production of such tablets, i. high content of active substance and low amounts of excipients would be possible.
Den her omhandlede fremgangsmåde muliggør en rationel fremstilling af tabletter, der har et højt indhold af anti-35 biotikum, og som er så små som mulige, ud fra et dårligt strømmende antibiotikum-pulver, nemlig af penicillin- ellerThe present process enables the rational preparation of tablets having a high content of anti-biotic and as small as possible from a poorly flowing antibiotic powder, namely penicillin or
OISLAND
3 U3436 cephalosporintypen, og fremgangsmåden er ejendommelig ved* at antibiotiket, der udgør 85-95% af tabletternes vægt, blandes med mindst tre hjælpestoffer valgt blandt krystallinsk cellulose, stivelse, stivelsesderivater, ultraamylopectin, 5 talkum og magnesiumstearat, hvorefter blandingen, eventuelt efter forudgående granulering, presses til tabletter.The type of cephalosporin type and the method is characterized in that the antibiotic constituting 85-95% of the weight of the tablets is mixed with at least three excipients selected from crystalline cellulose, starch, starch derivatives, ultraamylopectin, talc and magnesium stearate, after which the mixture, if desired, granulation, pressed into tablets.
Andelene af de nævnte virksomme stoffer og hjælpestoffer forholder sig f.eks. som følger; 10 Antibiotikum 85-93%The proportions of the mentioned active substances and excipients relate, e.g. as follows; Antibiotic 85-93%
Krystallinsk cellulose 8-4%Crystalline cellulose 8-4%
Ultraamylopectin 5-2%Ultraamylopectin 5-2%
Magnesiumstearat 2-1% 15 Særlig gode strømegenskaber og derigennem den mest rationelle produktion ved den her omhandlede fremgangsmåde opnås ifølge opfindelsen ved,at antibiotiket blandes mød 10-2,5% krystallinsk cellulose, 3-1% ultraamylopectin og 2-1,0% magnesiumstearat, eller ved, at antibiotiket blandes med 20 8-2,6% stivelse eller stivelsesderivat, 5-2,0% talkum og 2-0,4% magnesiumstearat.Magnesium stearate 2-1% Particularly good flow properties and thereby the most rational production of the process according to the invention are achieved by mixing the antibiotic with 10-2.5% crystalline cellulose, 3-1% ultra-amylopectin and 2-1.0% magnesium stearate, or by mixing the antibiotic with 8-2.6% starch or starch derivative, 5-2.0% talc and 2-0.4% magnesium stearate.
Som antibiotika egner der sig fortrinsvis derivater af penicillin, f.eks. penicillin-V-kalium, ampicillin, oxacillin eller cephalosporin-derivater.As antibiotics, derivatives of penicillin, e.g. penicillin-V potassium, ampicillin, oxacillin or cephalosporin derivatives.
25 Krystallinsk cellulose er et ved oparbejdning af celluloseholdige materialer udvundet produkt.Crystalline cellulose is a product obtained by reprocessing of cellulosic materials.
Stivelse og stivelsesderivater er kendte som spræng-midler. Som stivelsesderivater kan f.eks. anvendes carboxy-methylstivelse eller "STAR RX 1.500", som er majsstivelse, 30 som er modificeret fysisk, således at dens vandopløselige andel er bragt op på ca. 20%.Starch and starch derivatives are known as explosives. As starch derivatives, e.g. For example, carboxy-methyl starch or "STAR RX 1,500", which is corn starch, is 30 which is physically modified so that its water-soluble content is raised to approx. 20%.
Ultraamylopectin er et stivelsesprodukt, der fås ved indvirkning af natriumalkoholat og halogenfedtsyrer på stivelse. Det tjener på grund af sin opkvældningsevne 35 som tabletsprængmiddel.Ultraamylopectin is a starch product obtained by the action of sodium alcoholate and halogen fatty acids on starch. It serves because of its swelling ability 35 as a tablet explosive.
U3436U3436
OISLAND
44
Magnesimnstearat og talkum er beskrevet i farmakopeen som smøre- og antiklæbemidler.Magnesium stearate and talc are described in the pharmacopoeia as lubricants and anti-adhesives.
Disse hjælpestofblandinger kan om nødvendigt tilsættes yderligere alment kendte tablethjælpestoffer.These auxiliary compositions may be added, if necessary, to other commonly known tablet adjuvants.
5 Naturligvis kan der ud fra de her omhandlede blandinqer også presses mindre tabletter jfr. krav 1 (f.eks. til børn) eller større tabletter jfr. krav 1 (f.eks. til vaginal indgivelse eller til dyr).Of course, from the mixtures in question, smaller tablets can also be pressed, cf. claim 1 (eg for children) or larger tablets cf. Claim 1 (for example, for vaginal or animal administration).
De eventuelt efter granulering dannede blandinger med 10 ovennævnte sammensætninger strømmer frit og kan fremstilles med dadelfri kvalitet på hurtigløbende maskiner i en mængde på ca. 2000 til ca. 3000 tabletter pr. minut.The mixtures possibly formed after granulation with the above-mentioned compositions flow freely and can be made with immaculate quality on fast-running machines in an amount of approx. 2000 to approx. 3000 tablets per day minute.
Alt efter vandopløseligheden af det virksomme stof henfalder tabletterne i vand eller kunstig mavesaft ved en 15 temperatur på 37°C på få minutter indtil maksimalt 6 minutter.Depending on the water solubility of the active substance, the tablets decay into water or artificial gastric juice at a temperature of 37 ° C for a few minutes to a maximum of 6 minutes.
De dannede tabletter kan på inden for farmacien sædvanlig måde overtrækkes med et (eventuelt aromatiseret) film-eller drageeover træk til beskyttelse mod påvirkning ude fra, f.eks. fugtighed og lys, og til smagsmaskering.The tablets formed can be coated in a conventional manner with a (optionally flavored) film or dragee coating for protection against external influences, e.g. humidity and light, and for taste masking.
2020
Eksempel 1Example 1
Tabletter med 1000 mg ampicillinTablets with 1000 mg ampicillin
Sammensætning:composition:
Ampicillintrihydrat 92,5% 25 svarende til 1000 mg ampicillinAmpicillin trihydrate 92.5% corresponding to 1000 mg of ampicillin
Krystallinsk cellulose 6,0%Crystalline cellulose 6.0%
Ultraamylopectin 1,0%Ultraamylopectin 1.0%
Magnesiumstearat 0,5% 100,0% 30Magnesium stearate 0.5% 100.0% 30
Fremstilling: I en hurtigblander fremstilles en blanding ud fra ovennævnte stoffer, og der fremstilles et granulat med en kornstørrelse mellem 2,0 og 0,3 mm.Preparation: In a quick mixer, a mixture is prepared from the above substances and a granule having a grain size between 2.0 and 0.3 mm is prepared.
35 Den granulerede blanding presses på en tabletrundløber til hvælvede oblorgtabletter (f.eks. 21 mm x 9 mm) med brudrille ved en hastighed på 2000 til 3000 tabletter pr. minut.35 The granulated mixture is pressed onto a tablet runner for vaulted oblorg tablets (eg 21 mm x 9 mm) with rupture groove at a rate of 2000 to 3000 tablets per minute. minute.
143436 5143436 5
OISLAND
Tabletterne henfalder i kunstig mavesaft ved 37°C i løbet af maksimalt 3 minutter.The tablets decay into artificial gastric juice at 37 ° C for a maximum of 3 minutes.
De formede legemer kan forsynes med et eventuelt aromatiseret film- eller dragéeovertræk.The shaped bodies may be provided with an optionally flavored film or dragee coating.
55
Eksempel 2Example 2
Tabletter med 1,2-mega-enheder penicillin-V-kalium. Sammensætning:Tablets with 1.2-mega units of penicillin-V potassium. composition:
Penicillin-V-kalium + 10% overdosering 93,0% 10 svarende til 1.320.000 I.E.Penicillin-V potassium + 10% overdose 93.0% 10 corresponding to 1,320,000 I.E.
Majsstivelse 3,5%Corn starch 3.5%
Talkum 3,0%Talc 3.0%
Magnesiumstearat 0,5% 100,0% 15Magnesium stearate 0.5% 100.0% 15
Fremstilling: I en hurtigblander fremstilles en blanding ud fra ovennævnte stoffer, og der fremstilles et granulat med en kornstørrelse mellem 2,0 og 0,3 mm.Preparation: In a quick mixer, a mixture is prepared from the above substances and a granule having a grain size between 2.0 and 0.3 mm is prepared.
20 Den granulerede blanding presses på en tabletrundløber til hvælvede oblongtabletter (f.eks. 19 x 8 mm) med brudrille ved en hastighed på ca. 2000 til 3000 tabletter pr. minut.20 The granulated mixture is pressed onto a tablet round for vaulted oblong tablets (e.g., 19 x 8 mm) with rupture groove at a speed of approx. 2000 to 3000 tablets per minute.
Tabletterne henfalder i kunstig mavesaft ved 37°C i løbet af maksimalt 5 til 6 minutter.The tablets decay into artificial gastric juice at 37 ° C for a maximum of 5 to 6 minutes.
25 De formede legemer kan forsynes med et eventuelt aromatiseret film- eller dragéeovertræk.The shaped bodies may be provided with an optionally flavored film or dragee coating.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE2251250A DE2251250C3 (en) | 1972-10-19 | 1972-10-19 | Process for the production of high-dose antibiotic tablets |
DE2251250 | 1972-10-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
DK143436B true DK143436B (en) | 1981-08-24 |
Family
ID=5859487
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK565773AA DK143436B (en) | 1972-10-19 | 1973-10-18 | PROCEDURE FOR PREPARING TABLETS WITH A HIGH CONTENT OF ANTIOB LD OF ANTIBIOTICS |
Country Status (10)
Country | Link |
---|---|
AT (1) | AT338430B (en) |
BE (1) | BE806294A (en) |
CH (1) | CH608964A5 (en) |
DE (1) | DE2251250C3 (en) |
DK (1) | DK143436B (en) |
FR (1) | FR2247208B1 (en) |
GB (1) | GB1451804A (en) |
NL (1) | NL7314085A (en) |
SE (1) | SE416176B (en) |
ZA (1) | ZA738100B (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4034035A (en) * | 1975-07-14 | 1977-07-05 | Merck & Co., Inc. | Method of preparing multi-toned tablets |
US4115563A (en) * | 1977-03-14 | 1978-09-19 | Sterling Drug Inc. | Pharmaceutical steroid formulation |
ES2061623T3 (en) * | 1987-03-02 | 1994-12-16 | Brocades Pharma Bv | PROCEDURE FOR OBTAINING A PHARMACEUTICAL COMPOSITION AND A PHARMACEUTICAL GRANULATE. |
EA003736B1 (en) * | 1995-02-08 | 2003-08-28 | Яманучи Юроп Б.В. | AN ORAL DOSAGE FORM CONTAINING A beta-LACTAM ANTIBIOTIC |
DK0890359T3 (en) * | 1996-02-29 | 2002-07-01 | Fujisawa Pharmaceutical Co | Beta-Lactam antibiotic-containing tablets and method of preparation thereof |
TWI225402B (en) * | 1996-03-13 | 2004-12-21 | Biochemie Gmbh | Auxiliary-free agglomerates |
AU6496498A (en) * | 1997-02-07 | 1998-08-26 | Gist-Brocades B.V. | Homogeneous granulated formulations for dose sipping technology |
EP1023065A1 (en) * | 1997-08-29 | 2000-08-02 | Dsm N.V. | Granules free of excipients |
EP0973520A1 (en) * | 1997-11-17 | 2000-01-26 | Gist-Brocades B.V. | Granules comprising clavulanate and one or more excipients |
CN114939113A (en) * | 2022-06-01 | 2022-08-26 | 澳美制药(苏州)有限公司 | Penicillin V potassium tablet and preparation method thereof |
-
1972
- 1972-10-19 DE DE2251250A patent/DE2251250C3/en not_active Expired
-
1973
- 1973-10-12 NL NL7314085A patent/NL7314085A/xx not_active Application Discontinuation
- 1973-10-16 CH CH1464573A patent/CH608964A5/en not_active IP Right Cessation
- 1973-10-17 SE SE7314143A patent/SE416176B/en unknown
- 1973-10-18 FR FR7337173A patent/FR2247208B1/fr not_active Expired
- 1973-10-18 AT AT884973A patent/AT338430B/en not_active IP Right Cessation
- 1973-10-18 ZA ZA00738100A patent/ZA738100B/en unknown
- 1973-10-18 DK DK565773AA patent/DK143436B/en not_active Application Discontinuation
- 1973-10-19 GB GB4883473A patent/GB1451804A/en not_active Expired
- 1973-10-19 BE BE136881A patent/BE806294A/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
AT338430B (en) | 1977-08-25 |
DE2251250A1 (en) | 1974-05-02 |
CH608964A5 (en) | 1979-02-15 |
DE2251250B2 (en) | 1979-10-04 |
FR2247208B1 (en) | 1978-11-03 |
GB1451804A (en) | 1976-10-06 |
ATA884973A (en) | 1976-12-15 |
DE2251250C3 (en) | 1981-06-25 |
SE416176B (en) | 1980-12-08 |
NL7314085A (en) | 1974-04-23 |
AU6151373A (en) | 1975-04-17 |
ZA738100B (en) | 1975-05-28 |
FR2247208A1 (en) | 1975-05-09 |
BE806294A (en) | 1974-04-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4587118A (en) | Dry sustained release theophylline oral formulation | |
DK175508B1 (en) | Pharmaceutical tablet, pharmaceutical granules and methods for preparing this tablet and granules respectively | |
EP0129382B1 (en) | Long-acting formulation of cefaclor and its preparation | |
US6030953A (en) | Pharmaceutical composition containing chitosan | |
US5211958A (en) | Pharmaceutical composition and process for its preparation | |
DK175620B1 (en) | Tablet matrix pharmaceutical formulation with delayed release of the active ingredient | |
DK144306B (en) | BASIC FOR USE IN PREPARING A PHARMACEUTICAL UNIT DOSAGE WITH SLOW RELEASE OF AN ACTIVE INGREDIENT AND PROCEDURES FOR PRODUCING THEREOF | |
US4301176A (en) | Method of administering calcium valproate | |
KR101370712B1 (en) | A combination composition | |
DK158540B (en) | ORAL, NON-RETARDED DIPYRIDAMOL FORMS AND PROCEDURES FOR THEIR PREPARATION | |
DK161014B (en) | METHOD FOR PREPARING DELAYED THERAPEUTIC PREPARATIONS ON HYDROXYPROPYLMETHYL CELLULOSE WITH HIGH MOLECULE WEIGHT | |
BG61677B1 (en) | Medicamentous form for oral application for the treatment of central disorders related to the absence of dopemine | |
DK143436B (en) | PROCEDURE FOR PREPARING TABLETS WITH A HIGH CONTENT OF ANTIOB LD OF ANTIBIOTICS | |
US2656298A (en) | Therapeutic product | |
NO309455B1 (en) | Film-coated tablet of acetaminophen and domperidone | |
KR100263284B1 (en) | More easily biologically absorbed tablet containing dichloromethylene diphosphonic acid as the active agent | |
IE912885A1 (en) | Multiparticulate sustained release matrix system | |
US2798024A (en) | Composite enteric tablet of erythromycin and sulfonamides | |
US3018221A (en) | Penicillin-sulfonamide tablet | |
US3931404A (en) | High dosage orally administrable cephalosporin antibiotic preparations | |
WO1993017679A1 (en) | Compositions containing ranitidine/bismuth carboxylates salts | |
KR20160002177A (en) | Pharmaceutical composition comprising oseltamivir free base | |
DK175526B1 (en) | Pharmaceutical composition and process for its preparation | |
KR20230086370A (en) | Pharmaceutical combination comprising dapagliflozin and pioglitazone and preparing method thereof | |
US2866735A (en) | Therapeutic composition of matter |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PTS | Application withdrawn |